• Hutchison MediPharma Ltd., of London, began a Phase I trial of theliatinib (HMPL-309) in advanced solid tumors. The objectives of the study are safety and tolerability, as well as determining the maximum tolerated dose. Efficacy against non-small-cell lung cancer and pharmacokinetics also will be evaluated. Theliatinib is an inhibitor of epidermal growth factor receptor (EGFR) that has shown strong antitumor activity against EGFR wild-type tumors in preclinical studies.